Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.